APO Research
Talk to an analyst

APO RESEARCH · REPORT

Bevacizumab Injection

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Bevacizumab Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

2 January 2026197 pages

Choose your research edition.

Industry ResearchBevacizumab Injection Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Bevacizumab Injection Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Bevacizumab Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Bevacizumab Injection Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Bevacizumab Injection Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Bevacizumab Injection market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Bevacizumab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Bevacizumab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Bevacizumab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Bevacizumab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Bevacizumab Injection include Biocon, Cadila Pharmaceuticals, Centus, Dr Reddy's, Genentech, Hetero Group, Samsung Bioepis, Amgen and Bayer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Bevacizumab Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Bevacizumab Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Bevacizumab Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Bevacizumab Injection market size, projected growth trends, production technologies, key applications, and end-use industries.

Bevacizumab Injection Segment by Company

Biocon

Cadila Pharmaceuticals

Centus

Dr Reddy's

Genentech

Hetero Group

Samsung Bioepis

Amgen

Bayer

Pfizer

Eli Lilly

Roche

Mylan

Bevacizumab Injection Segment by Type

100mg

400mg

Bevacizumab Injection Segment by Application

Age-related macular degeneration (AMD)

Ovarian Cancer

Others

Bevacizumab Injection Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bevacizumab Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Bevacizumab Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bevacizumab Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Bevacizumab Injection market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Bevacizumab Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Bevacizumab Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Bevacizumab Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Bevacizumab Injection Industry Trends Table 2. Bevacizumab Injection Industry Drivers Table 3. Bevacizumab Injection Industry Opportunities and Challenges Table 4. Bevacizumab Injection Industry Restraints Table 5. Global Bevacizumab Injection Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Bevacizumab Injection Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Bevacizumab Injection Sales by Manufacturers (K Doses) & (2021-2026) Table 8. Global Bevacizumab Injection Sales Market Share by Manufacturers Table 9. Global Bevacizumab Injection Average Sales Price (US$/Dose) of Manufacturers (2021-2026) Table 10. Global Bevacizumab Injection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Bevacizumab Injection Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Bevacizumab Injection Manufacturers, Product Type & Application Table 13. Global Bevacizumab Injection Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Bevacizumab Injection by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of 100mg Table 17. Major Manufacturers of 400mg Table 18. Global Bevacizumab Injection Sales by Type 2021 VS 2025 VS 2032 (K Doses) Table 19. Global Bevacizumab Injection Sales by Type (2021-2026) & (K Doses) Table 20. Global Bevacizumab Injection Sales by Type (2027-2032) & (K Doses) Table 21. Global Bevacizumab Injection Sales Market Share by Type (2021-2026) Table 22. Global Bevacizumab Injection Sales Market Share by Type (2027-2032) Table 23. Global Bevacizumab Injection Revenue by Type 2021 VS 2025 VS 2032 (K Doses) Table 24. Global Bevacizumab Injection Revenue by Type (2021-2026) & (K Doses) Table 25. Global Bevacizumab Injection Revenue by Type (2027-2032) & (K Doses) Table 26. Global Bevacizumab Injection Revenue Market Share by Type (2021-2026) Table 27. Global Bevacizumab Injection Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Age-related macular degeneration (AMD) Table 29. Major Manufacturers of Ovarian Cancer Table 30. Major Manufacturers of Others Table 31. Global Bevacizumab Injection Sales by Application 2021 VS 2025 VS 2032 (K Doses) Table 32. Global Bevacizumab Injection Sales by Application (2021-2026) & (K Doses) Table 33. Global Bevacizumab Injection Sales by Application (2027-2032) & (K Doses) Table 34. Global Bevacizumab Injection Sales Market Share by Application (2021-2026) Table 35. Global Bevacizumab Injection Sales Market Share by Application (2027-2032) Table 36. Global Bevacizumab Injection Revenue by Application 2021 VS 2025 VS 2032 (K Doses) Table 37. Global Bevacizumab Injection Revenue by Application (2021-2026) & (K Doses) Table 38. Global Bevacizumab Injection Revenue by Application (2027-2032) & (K Doses) Table 39. Global Bevacizumab Injection Revenue Market Share by Application (2021-2026) Table 40. Global Bevacizumab Injection Revenue Market Share by Application (2027-2032) Table 41. Global Bevacizumab Injection Sales by Region: 2021 VS 2025 VS 2032 (K Doses) Table 42. Global Bevacizumab Injection Sales by Region (2021-2026) & (K Doses) Table 43. Global Bevacizumab Injection Sales Market Share by Region (2021-2026) Table 44. Global Bevacizumab Injection Sales Forecasted by Region (2027-2032) & (K Doses) Table 45. Global Bevacizumab Injection Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Bevacizumab Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Doses) Table 47. North America Bevacizumab Injection Sales by Country (2021-2026) & (K Doses) Table 48. North America Bevacizumab Injection Sales by Country (2027-2032) & (K Doses) Table 49. Europe Bevacizumab Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Doses) Table 50. Europe Bevacizumab Injection Sales by Country (2021-2026) & (K Doses) Table 51. Europe Bevacizumab Injection Sales by Country (2027-2032) & (K Doses) Table 52. Asia Pacific Bevacizumab Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Doses) Table 53. Asia Pacific Bevacizumab Injection Sales by Country (2021-2026) & (K Doses) Table 54. Asia Pacific Bevacizumab Injection Sales by Country (2027-2032) & (K Doses) Table 55. South America, Middle East and Africa Bevacizumab Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Doses) Table 56. South America, Middle East and Africa Bevacizumab Injection Sales by Country (2021-2026) & (K Doses) Table 57. South America, Middle East and Africa Bevacizumab Injection Sales by Country (2027-2032) & (K Doses) Table 58. Global Bevacizumab Injection Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Bevacizumab Injection Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Bevacizumab Injection Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Bevacizumab Injection Revenue Market Share by Region (2021-2026) Table 62. Global Bevacizumab Injection Revenue Market Share by Region (2027-2032) Table 63. Biocon Company Information Table 64. Biocon Business Overview Table 65. Biocon Bevacizumab Injection Sales (K Doses), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Biocon Bevacizumab Injection Product Portfolio Table 67. Biocon Recent Development Table 68. Cadila Pharmaceuticals Company Information Table 69. Cadila Pharmaceuticals Business Overview Table 70. Cadila Pharmaceuticals Bevacizumab Injection Sales (K Doses), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Cadila Pharmaceuticals Bevacizumab Injection Product Portfolio Table 72. Cadila Pharmaceuticals Recent Development Table 73. Centus Company Information Table 74. Centus Business Overview Table 75. Centus Bevacizumab Injection Sales (K Doses), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Centus Bevacizumab Injection Product Portfolio Table 77. Centus Recent Development Table 78. Dr Reddy's Company Information Table 79. Dr Reddy's Business Overview Table 80. Dr Reddy's Bevacizumab Injection Sales (K Doses), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Dr Reddy's Bevacizumab Injection Product Portfolio Table 82. Dr Reddy's Recent Development Table 83. Genentech Company Information Table 84. Genentech Business Overview Table 85. Genentech Bevacizumab Injection Sales (K Doses), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Genentech Bevacizumab Injection Product Portfolio Table 87. Genentech Recent Development Table 88. Hetero Group Company Information Table 89. Hetero Group Business Overview Table 90. Hetero Group Bevacizumab Injection Sales (K Doses), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Hetero Group Bevacizumab Injection Product Portfolio Table 92. Hetero Group Recent Development Table 93. Samsung Bioepis Company Information Table 94. Samsung Bioepis Business Overview Table 95. Samsung Bioepis Bevacizumab Injection Sales (K Doses), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Samsung Bioepis Bevacizumab Injection Product Portfolio Table 97. Samsung Bioepis Recent Development Table 98. Amgen Company Information Table 99. Amgen Business Overview Table 100. Amgen Bevacizumab Injection Sales (K Doses), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Amgen Bevacizumab Injection Product Portfolio Table 102. Amgen Recent Development Table 103. Bayer Company Information Table 104. Bayer Business Overview Table 105. Bayer Bevacizumab Injection Sales (K Doses), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Bayer Bevacizumab Injection Product Portfolio Table 107. Bayer Recent Development Table 108. Pfizer Company Information Table 109. Pfizer Business Overview Table 110. Pfizer Bevacizumab Injection Sales (K Doses), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Pfizer Bevacizumab Injection Product Portfolio Table 112. Pfizer Recent Development Table 113. Eli Lilly Company Information Table 114. Eli Lilly Business Overview Table 115. Eli Lilly Bevacizumab Injection Sales (K Doses), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Eli Lilly Bevacizumab Injection Product Portfolio Table 117. Eli Lilly Recent Development Table 118. Roche Company Information Table 119. Roche Business Overview Table 120. Roche Bevacizumab Injection Sales (K Doses), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Roche Bevacizumab Injection Product Portfolio Table 122. Roche Recent Development Table 123. Mylan Company Information Table 124. Mylan Business Overview Table 125. Mylan Bevacizumab Injection Sales (K Doses), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Mylan Bevacizumab Injection Product Portfolio Table 127. Mylan Recent Development Table 128. Key Raw Materials Table 129. Raw Materials Key Suppliers Table 130. Bevacizumab Injection Distributors List Table 131. Bevacizumab Injection Customers List Table 132. Research Programs/Design for This Report Table 133. Authors List of This Report Table 134. Secondary Sources Table 135. Primary Sources List of Figures Figure 1. Bevacizumab Injection Product Image Figure 2. Global Bevacizumab Injection Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Bevacizumab Injection Market Size (2021-2032) & (US$ Million) Figure 4. Global Bevacizumab Injection Sales (2021-2032) & (K Doses) Figure 5. Global Bevacizumab Injection Average Price (US$/Dose) & (2021-2032) Figure 6. Global Top 5 and 10 Bevacizumab Injection Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. 100mg Image Figure 9. 400mg Image Figure 10. Global Bevacizumab Injection Sales by Type (2021 VS 2025 VS 2032) & (K Doses) Figure 11. Global Bevacizumab Injection Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Bevacizumab Injection Sales Market Share by Type (2021-2032) Figure 13. Global Bevacizumab Injection Revenue by Type (2021 VS 2025 VS 2032) & (K Doses) Figure 14. Global Bevacizumab Injection Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Bevacizumab Injection Revenue Market Share by Type (2021-2032) Figure 16. Age-related macular degeneration (AMD) Image Figure 17. Ovarian Cancer Image Figure 18. Others Image Figure 19. Global Bevacizumab Injection Sales by Application (2021 VS 2025 VS 2032) & (K Doses) Figure 20. Global Bevacizumab Injection Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Bevacizumab Injection Sales Market Share by Application (2021-2032) Figure 22. Global Bevacizumab Injection Revenue by Application (2021 VS 2025 VS 2032) & (K Doses) Figure 23. Global Bevacizumab Injection Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Bevacizumab Injection Revenue Market Share by Application (2021-2032) Figure 25. North America Bevacizumab Injection Sales and Growth Rate (2021-2032) & (K Doses) Figure 26. North America Bevacizumab Injection Sales Market Share by Country (2021-2032) Figure 27. U.S. Bevacizumab Injection Sales and Growth Rate (2021-2032) & (K Doses) Figure 28. Canada Bevacizumab Injection Sales and Growth Rate (2021-2032) & (K Doses) Figure 29. Mexico Bevacizumab Injection Sales and Growth Rate (2021-2032) & (K Doses) Figure 30. Europe Bevacizumab Injection Sales and Growth Rate (2021-2032) & (K Doses) Figure 31. Europe Bevacizumab Injection Sales Market Share by Country (2021-2032) Figure 32. Germany Bevacizumab Injection Sales and Growth Rate (2021-2032) & (K Doses) Figure 33. France Bevacizumab Injection Sales and Growth Rate (2021-2032) & (K Doses) Figure 34. U.K. Bevacizumab Injection Sales and Growth Rate (2021-2032) & (K Doses) Figure 35. Italy Bevacizumab Injection Sales and Growth Rate (2021-2032) & (K Doses) Figure 36. Netherlands Bevacizumab Injection Sales and Growth Rate (2021-2032) & (K Doses) Figure 37. Asia Pacific Bevacizumab Injection Sales and Growth Rate (2021-2032) & (K Doses) Figure 38. Asia Pacific Bevacizumab Injection Sales Market Share by Country (2021-2032) Figure 39. China Bevacizumab Injection Sales and Growth Rate (2021-2032) & (K Doses) Figure 40. Japan Bevacizumab Injection Sales and Growth Rate (2021-2032) & (K Doses) Figure 41. South Korea Bevacizumab Injection Sales and Growth Rate (2021-2032) & (K Doses) Figure 42. Southeast Asia Bevacizumab Injection Sales and Growth Rate (2021-2032) & (K Doses) Figure 43. India Bevacizumab Injection Sales and Growth Rate (2021-2032) & (K Doses) Figure 44. Australia Bevacizumab Injection Sales and Growth Rate (2021-2032) & (K Doses) Figure 45. South America, Middle East and Africa Bevacizumab Injection Sales and Growth Rate (2021-2032) & (K Doses) Figure 46. South America, Middle East and Africa Bevacizumab Injection Sales Market Share by Country (2021-2032) Figure 47. Brazil Bevacizumab Injection Sales and Growth Rate (2021-2032) & (K Doses) Figure 48. South Africa Bevacizumab Injection Sales and Growth Rate (2021-2032) & (K Doses) Figure 49. Saudi Arabia Bevacizumab Injection Sales and Growth Rate (2021-2032) & (K Doses) Figure 50. Turkey Bevacizumab Injection Sales and Growth Rate (2021-2032) & (K Doses) Figure 51. Argentina Bevacizumab Injection Sales and Growth Rate (2021-2032) & (K Doses) Figure 52. UAE Bevacizumab Injection Sales and Growth Rate (2021-2032) & (K Doses) Figure 53. Egypt Bevacizumab Injection Sales and Growth Rate (2021-2032) & (K Doses) Figure 54. Chile Bevacizumab Injection Sales and Growth Rate (2021-2032) & (K Doses) Figure 55. Global Bevacizumab Injection Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Bevacizumab Injection Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Bevacizumab Injection Revenue (2021-2032) & (US$ Million) Figure 58. North America Bevacizumab Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Bevacizumab Injection Revenue (2021-2032) & (US$ Million) Figure 60. Europe Bevacizumab Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Bevacizumab Injection Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Bevacizumab Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Bevacizumab Injection Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Bevacizumab Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Bevacizumab Injection Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Bevacizumab Injection Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • 100mg
  • 400mg
Applications
  • Age-related macular degeneration (AMD)
  • Ovarian Cancer
  • Others
Companies covered
  • Biocon
  • Cadila Pharmaceuticals
  • Centus
  • Dr Reddy's
  • Genentech
  • Hetero Group
  • Samsung Bioepis
  • Amgen
  • Bayer
  • Pfizer
  • Eli Lilly
  • Roche
  • Mylan

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Bevacizumab Injection Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Bevacizumab Injection Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Bevacizumab Injection Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Bevacizumab Injection Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Bevacizumab Injection Market Dynamics
  1. 2.1 Bevacizumab Injection Industry Trends
  2. 2.2 Bevacizumab Injection Industry Drivers
  3. 2.3 Bevacizumab Injection Industry Opportunities and Challenges
  4. 2.4 Bevacizumab Injection Industry Restraints
3 Bevacizumab Injection Market by Manufacturers
  1. 3.1 Global Bevacizumab Injection Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Bevacizumab Injection Sales by Manufacturers (2021-2026)
  3. 3.3 Global Bevacizumab Injection Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Bevacizumab Injection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Bevacizumab Injection Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Bevacizumab Injection Manufacturers, Product Type & Application
  7. 3.7 Global Bevacizumab Injection Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Bevacizumab Injection Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Bevacizumab Injection Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Bevacizumab Injection Tier 1, Tier 2, and Tier 3
4 Bevacizumab Injection Market by Type
  1. 4.1 Bevacizumab Injection Type Introduction
  2. 4.1.1 100mg
  3. 4.1.2 400mg
  4. 4.2 Global Bevacizumab Injection Sales by Type
  5. 4.2.1 Global Bevacizumab Injection Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Bevacizumab Injection Sales by Type (2021-2032)
  7. 4.2.3 Global Bevacizumab Injection Sales Market Share by Type (2021-2032)
  8. 4.3 Global Bevacizumab Injection Revenue by Type
  9. 4.3.1 Global Bevacizumab Injection Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Bevacizumab Injection Revenue by Type (2021-2032)
  11. 4.3.3 Global Bevacizumab Injection Revenue Market Share by Type (2021-2032)
5 Bevacizumab Injection Market by Application
  1. 5.1 Bevacizumab Injection Application Introduction
  2. 5.1.1 Age-related macular degeneration (AMD)
  3. 5.1.2 Ovarian Cancer
  4. 5.1.3 Others
  5. 5.2 Global Bevacizumab Injection Sales by Application
  6. 5.2.1 Global Bevacizumab Injection Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Bevacizumab Injection Sales by Application (2021-2032)
  8. 5.2.3 Global Bevacizumab Injection Sales Market Share by Application (2021-2032)
  9. 5.3 Global Bevacizumab Injection Revenue by Application
  10. 5.3.1 Global Bevacizumab Injection Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Bevacizumab Injection Revenue by Application (2021-2032)
  12. 5.3.3 Global Bevacizumab Injection Revenue Market Share by Application (2021-2032)
6 Global Bevacizumab Injection Sales by Region
  1. 6.1 Global Bevacizumab Injection Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Bevacizumab Injection Sales by Region (2021-2032)
  3. 6.2.1 Global Bevacizumab Injection Sales by Region (2021-2026)
  4. 6.2.2 Global Bevacizumab Injection Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Bevacizumab Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Bevacizumab Injection Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Bevacizumab Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Bevacizumab Injection Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Bevacizumab Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Bevacizumab Injection Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Bevacizumab Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Bevacizumab Injection Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Bevacizumab Injection Revenue by Region
  1. 7.1 Global Bevacizumab Injection Revenue by Region
  2. 7.1.1 Global Bevacizumab Injection Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Bevacizumab Injection Revenue by Region (2021-2026)
  4. 7.1.3 Global Bevacizumab Injection Revenue by Region (2027-2032)
  5. 7.1.4 Global Bevacizumab Injection Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Bevacizumab Injection Revenue (2021-2032)
  8. 7.2.2 North America Bevacizumab Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Bevacizumab Injection Revenue (2021-2032)
  11. 7.3.2 Europe Bevacizumab Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Bevacizumab Injection Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Bevacizumab Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Bevacizumab Injection Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Bevacizumab Injection Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Biocon
  2. 8.1.1 Biocon Company Information
  3. 8.1.2 Biocon Business Overview
  4. 8.1.3 Biocon Bevacizumab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Biocon Bevacizumab Injection Product Portfolio
  6. 8.1.5 Biocon Recent Developments
  7. 8.2 Cadila Pharmaceuticals
  8. 8.2.1 Cadila Pharmaceuticals Company Information
  9. 8.2.2 Cadila Pharmaceuticals Business Overview
  10. 8.2.3 Cadila Pharmaceuticals Bevacizumab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Cadila Pharmaceuticals Bevacizumab Injection Product Portfolio
  12. 8.2.5 Cadila Pharmaceuticals Recent Developments
  13. 8.3 Centus
  14. 8.3.1 Centus Company Information
  15. 8.3.2 Centus Business Overview
  16. 8.3.3 Centus Bevacizumab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Centus Bevacizumab Injection Product Portfolio
  18. 8.3.5 Centus Recent Developments
  19. 8.4 Dr Reddy's
  20. 8.4.1 Dr Reddy's Company Information
  21. 8.4.2 Dr Reddy's Business Overview
  22. 8.4.3 Dr Reddy's Bevacizumab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Dr Reddy's Bevacizumab Injection Product Portfolio
  24. 8.4.5 Dr Reddy's Recent Developments
  25. 8.5 Genentech
  26. 8.5.1 Genentech Company Information
  27. 8.5.2 Genentech Business Overview
  28. 8.5.3 Genentech Bevacizumab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Genentech Bevacizumab Injection Product Portfolio
  30. 8.5.5 Genentech Recent Developments
  31. 8.6 Hetero Group
  32. 8.6.1 Hetero Group Company Information
  33. 8.6.2 Hetero Group Business Overview
  34. 8.6.3 Hetero Group Bevacizumab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Hetero Group Bevacizumab Injection Product Portfolio
  36. 8.6.5 Hetero Group Recent Developments
  37. 8.7 Samsung Bioepis
  38. 8.7.1 Samsung Bioepis Company Information
  39. 8.7.2 Samsung Bioepis Business Overview
  40. 8.7.3 Samsung Bioepis Bevacizumab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Samsung Bioepis Bevacizumab Injection Product Portfolio
  42. 8.7.5 Samsung Bioepis Recent Developments
  43. 8.8 Amgen
  44. 8.8.1 Amgen Company Information
  45. 8.8.2 Amgen Business Overview
  46. 8.8.3 Amgen Bevacizumab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Amgen Bevacizumab Injection Product Portfolio
  48. 8.8.5 Amgen Recent Developments
  49. 8.9 Bayer
  50. 8.9.1 Bayer Company Information
  51. 8.9.2 Bayer Business Overview
  52. 8.9.3 Bayer Bevacizumab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Bayer Bevacizumab Injection Product Portfolio
  54. 8.9.5 Bayer Recent Developments
  55. 8.10 Pfizer
  56. 8.10.1 Pfizer Company Information
  57. 8.10.2 Pfizer Business Overview
  58. 8.10.3 Pfizer Bevacizumab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Pfizer Bevacizumab Injection Product Portfolio
  60. 8.10.5 Pfizer Recent Developments
  61. 8.11 Eli Lilly
  62. 8.11.1 Eli Lilly Company Information
  63. 8.11.2 Eli Lilly Business Overview
  64. 8.11.3 Eli Lilly Bevacizumab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Eli Lilly Bevacizumab Injection Product Portfolio
  66. 8.11.5 Eli Lilly Recent Developments
  67. 8.12 Roche
  68. 8.12.1 Roche Company Information
  69. 8.12.2 Roche Business Overview
  70. 8.12.3 Roche Bevacizumab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Roche Bevacizumab Injection Product Portfolio
  72. 8.12.5 Roche Recent Developments
  73. 8.13 Mylan
  74. 8.13.1 Mylan Company Information
  75. 8.13.2 Mylan Business Overview
  76. 8.13.3 Mylan Bevacizumab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Mylan Bevacizumab Injection Product Portfolio
  78. 8.13.5 Mylan Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Bevacizumab Injection Value Chain Analysis
  2. 9.1.1 Bevacizumab Injection Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Bevacizumab Injection Production Mode & Process
  6. 9.2 Bevacizumab Injection Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Bevacizumab Injection Distributors
  9. 9.2.3 Bevacizumab Injection Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst